Business
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":" BAUDETTE, Minn.--(BUSINESS WIRE)--\n\nANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.\n\n“We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023. This transaction bears further testament to ANI’s strength in business development and complements the significant investment and efforts of our internal research and development team to bring much-needed medicines to patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.\n\nTransaction Advisor\n\nBourne Partners served as the exclusive financial advisor to Oakrum Pharma, LLC in this transaction.\n\nAbout ANI\n\nANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.\n\nForward-Looking Statements\n\nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company’s generic pipeline, other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.\n\nUncertainties and risks may cause the Company’s actual results to be materially different from those expressed in or implied by suc...